Literature DB >> 2829795

Prophylaxis and therapy of virulent encephalomyocarditis virus infection in mice by monoclonal antibodies. Brief report.

F Vlaspolder1, C A Kraaijeveld, R van Buuren, M Harmsen, B J Benaissa-Trouw, H Snippe.   

Abstract

Two encephalomyocarditis virus (EMCV) neutralizing monoclonal antibodies (MAs), recognizing different determinants on EMCV, were both able to protect mice prophylactically and therapeutically against a lethal dose of EMCV.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2829795     DOI： 10.1007/BF01321013

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  21 in total

1.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

2.  Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies.

Authors:  J W Stave; J L Card; D O Morgan
Journal:  J Gen Virol       Date:  1986-10       Impact factor: 3.891

3.  Peroxidase-labeled antibody. A new method of conjugation.

Authors:  P K Nakane; A Kawaoi
Journal:  J Histochem Cytochem       Date:  1974-12       Impact factor: 2.479

4.  Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines.

Authors:  G Köhler; S C Howe; C Milstein
Journal:  Eur J Immunol       Date:  1976-04       Impact factor: 5.532

Review 5.  Monoclonal antibodies: a powerful tool for selecting and analyzing mutations in antigens and antibodies.

Authors:  R R Pollock; J L Teillaud; M D Scharff
Journal:  Annu Rev Microbiol       Date:  1984       Impact factor: 15.500

Review 6.  Production of monoclonal antibodies: strategy and tactics.

Authors:  S F de StGroth; D Scheidegger
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

Review 7.  Picornaviral structure and assembly.

Authors:  J R Putnak; B A Phillips
Journal:  Microbiol Rev       Date:  1981-06

8.  Immunization of mice with live attenuated encephalomyocarditis virus: local immunity and survival.

Authors:  W J Bogaerts
Journal:  Infect Immun       Date:  1973-10       Impact factor: 3.441

9.  Effect of the adjuvant dimethyl dioctadecyl ammonium bromide on the humoral and cellular immune responses to encephalomyocarditis virus.

Authors:  C A Kraaijeveld; G la Rivière; B J Benaissa-Trouw; J Jansen; T Harmsen; H Snippe
Journal:  Antiviral Res       Date:  1983-09       Impact factor: 5.970

10.  Identification of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities.

Authors:  W A Boere; T Harmsen; J Vinjé; B J Benaissa-Trouw; C A Kraaijeveld; H Snippe
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103
View more
  6 in total

1.  IgVH determined genetic restriction of a non-internal image monoclonal anti-idiotypic vaccine against Semliki Forest virus.

Authors:  T A Oosterlaken; M Harmsen; G L Ekstijn; C A Kraaijeveld; H Snippe
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

2.  Blocking by anti-idiotypic antibodies of monoclonal antibody mediated protection in mice against encephalomyocarditis virus induced diabetes and lethal disease.

Authors:  F Vlaspolder; T A Oosterlaken; M Harmsen; P W van Dijk; H Kievit; C A Kraaijeveld; H Snippe
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

3.  A protective monoclonal anti-idiotypic vaccine to lethal Semliki Forest virus infection in BALB/c mice.

Authors:  T A Oosterlaken; M Harmsen; S S Jhagjhoor-Singh; G L Ekstijn; C A Kraaijeveld; H Snippe
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

4.  Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.

Authors:  I M Fernández; A Snijders; B J Benaissa-Trouw; M Harmsen; H Snippe; C A Kraaijeveld
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

5.  Application of immunoassay of encephalomyocarditis virus in cell culture with enzyme-labeled virus-specific monoclonal antibodies for rapid detection of virus, neutralizing antibodies, and interferon.

Authors:  F Vlaspolder; T Harmsen; D van Veenendaal; C A Kraaijeveld; H Snippe
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

6.  c-FLIP-Short reduces type I interferon production and increases viremia with coxsackievirus B3.

Authors:  Iwona A Buskiewicz; Andreas Koenig; Brian Roberts; Jennifer Russell; Cuixia Shi; Sun-Hwa Lee; Jae U Jung; Sally A Huber; Ralph C Budd
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.